Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antiviral drug
topical microbicide |
| gptkbp:activeIngredient |
tenofovir
|
| gptkbp:ATCCode |
J05AF07
|
| gptkbp:clinicalTrialPhase |
CAPRISA 004
VOICE trial |
| gptkbp:compatibleWith |
gptkb:FDA
gptkb:EMA |
| gptkbp:developedBy |
gptkb:CONRAD
gptkb:Gilead_Sciences |
| gptkbp:firstReported |
2008
|
| gptkbp:form |
gptkb:1%_tenofovir_gel
|
| https://www.w3.org/2000/01/rdf-schema#label |
tenofovir gel
|
| gptkbp:mechanismOfAction |
reverse transcriptase inhibitor
|
| gptkbp:notableAchievement |
reduced HSV-2 acquisition by 51% in CAPRISA 004 trial
reduced HIV acquisition by 39% in CAPRISA 004 trial |
| gptkbp:relatedTo |
gptkb:tenofovir_disoproxil_fumarate
oral pre-exposure prophylaxis (PrEP) |
| gptkbp:routeOfAdministration |
vaginal
rectal |
| gptkbp:sideEffect |
mild diarrhea
genital irritation |
| gptkbp:status |
investigational
|
| gptkbp:usedFor |
HIV prevention
HSV-2 prevention |
| gptkbp:bfsParent |
gptkb:CAPRISA_004_trial
|
| gptkbp:bfsLayer |
7
|